The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
the thing that surprised me amanda when i looked at the distribution of drugs just again this is available on clinicaltrials.gov is that 80 of the drugs are disease-modifying drugs which is a good sign of course because the other 20 as you said are symptomatic
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
as it stands today there are about 120 drugs in the pipeline um if my number crunching has it right about 27 of them if we extracted this correctly off clinicaltrials.gov are in phase one so for the listener meaning these are drugs that are really just being evaluated for safety at this point so we have some animal data that suggests this is a good idea we have no idea if it works in humans but in in a very small way with dose escalation we want to make sure it's safe about 65 are in phase two so that means they've passed that bar of being safe or at least safe enough to proceed to phase two where now we're looking for some efficacy and will of course continue to monitor safety and then 29 are in phase 3 which means at a small scale they've shown efficacy typically against a placebo now we want to see if there's efficacy again either versus a placebo or ideally against a current standard in a larger trial where again we're always going to continue to monitor safety but it's really this third stage that is required for fda approval
Another way to slice the data is to look at it by category of drug and i found this to be the most interesting 12 of these are in the space of cognitive enhancement 12 are in the space of neuropsychiatric and behavioral improvement and 97 are in the space of disease modification
that 80 percent of the drugs are disease modifying drugs which is a good sign of course because the other 20 as you said are symptomatic